iBio (IBIO) Long-Term Deferred Tax (2011 - 2012)
iBio's (IBIO) quarterly Long-Term Deferred Tax came in at $8.5 million in Q2 2012, up 37.24% year-on-year from $6.2 million in Q3 2011, and up 37.24% on a QoQ basis from $6.2 million in Q2 2011.
iBio (IBIO) Long-Term Deferred Tax (2011 - 2012) Analysis & Trends
iBio (IBIO) has 2 years of Long-Term Deferred Tax data on file, last reported at $8.5 million in Q2 2012.
- On a quarterly basis, Long-Term Deferred Tax rose 37.24% year-over-year to $8.5 million in Q2 2012; TTM through Jun 2012 was $8.5 million, a 37.24% increase from a year earlier, with the FY2012 full-year figure at $8.5 million, up 37.24% from the prior year.
- Long-Term Deferred Tax for Q2 2012 stood at $8.5 million, up from $6.2 million in the prior quarter.
- Over the last five years, Long-Term Deferred Tax for IBIO reached as high as $8.5 million in Q2 2012 and fell as low as $6.2 million in Q2 2011.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | iBio | 172.22 Mn | 172.22 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2012 | 8.53 Mn |
| Jun 30, 2011 | 6.22 Mn |